Avicanna Inc · TSX:AVCN
Avicanna — Investor Presentation (March 2019)
18 slides from Avicanna's investor presentation, March 2019
Slide 1: Innovation in R&D and cultivation in the cannabis industry
Innovation in R&D and cultivation in the cannabis industry March 2019 Avicanna.com
Slide 2: Corporate highlights
Avicanna TM Corporate highlights • Multi-national & strategically positioned • Clinical partnerships with world-renowned medical In North America and Latin America Institutions including The University of Toronto (”U of T”), University Health Network (“UHN”), The Hospital for Sick • Cultivation and
Slide 3: About Avicanna
About Avicanna TM Strategically positioned to be a front runner in the development, manufacturing and commercialization of plant-derived cannabinoid-based products. R&D CULTIVATION MANUFACTURING Headquartered in JLABS @ Low cost, industrial scale GMP manufacturing (Health Canada)* Toronto, in the Ma
Slide 4: Research and Development (R&D)
Research and Development (R&D) A dedication to robust scientific development and evidenced-based clinical approach 20+ Clinical development programs Ongoing clinical development programs to Collaboration of scientists demonstrate product safety and efficacy Operating out of Toronto, Bogota with world
Slide 5: Cultivation projects in Santa Marta, Colombia
Cultivation projects in Santa Marta, Colombia Controlling interest in two companies 60% interest 16 hectares in Colombia focused on commercial [180,000 sq ft current capacity, cannabis cultivation, Sativa Nativa and 290,000 sq ft completed Santa Marta Golden Hemp phase 1 project*] 70% interest 2.8 h
Slide 6: Environmentally Sustainable Cannabis Cultivation in Santa Marta Colombia
Environmentally Sustainable Cannabis Cultivation in Santa Marta Colombia Sun-grown and environmentally 1 sustainable practices Competitive cost advantages 2 including low cost labour, land and energy Cultivated under good agricultural 3 and collection practices (GACP) Avicanna’s proprietary extracti
Slide 7: Fully Licensed and Operating Cultivation Subsidiaries
2 Fully Licensed and Operating Cultivation Subsidiaries Santa Marta, Colombia Santa Marta Golden Hemp ("SMGH") and Sativa Nativa ("SN") capacity Current SMGH SN Total Current Cultivation Footprint 180,000 sq ft 70,000 sq ft 250,000 sq ft Current Annual Capacity 12,000 kg 3,000 kg 15,000 kg Phase 1 (
Slide 8: Extracts and API's
Extracts and API’s Avicanna’s extracts and pharmaceutical grade cannabinoids as active pharmaceutical ingredients (API) provided through its two subsidiaries in Santa Marta, Colombia Avicanna’s analytical laboratory and extraction laboratory in SMGH with capabilities to extract and isolate cannabino
Slide 9: GMP - Manufacturing partnership
GMP - Manufacturing partnership Altea Farma* Global GMP GMP Dosage Certifications Manufacturing of Forms • INVIMA (Colombia) • Pharmaceutical products • Gels, creams, • HEALTH CANADA • Phyto-therapeutics products drops, lotions • ANVISA (Brazil) • Dietary supplement products • Tablets, capsules, pel
Slide 10: WWW.PURAEARTH.WORLD
WWW.PURAEARTH.WORLD
Slide 11: Pura Earth CBD Derma-Cosmetics
Pura Earth™ CBD Derma-Cosmetics Derma-cosmetic formulations to maintain and improve the health and beauty of the skin. MOISTURIZE & PROTECTION clear skin Intensive SPECIALIZED conditioning • Anti-aging Treatment t r e at m e n t t r e at m e n t CARE • Under Eye Treatment CBD+ CBD+ BEAUTY Ro s e m a
Slide 12: To continue to advance the world of cannabinoid-based therapies
To continue to advance the world of cannabinoid-based therapies
Slide 13: Pura Elements CBD-THC Phyto-therapeutics
Pura Elements™ CBD-THC Phyto-therapeutics Plant-derived cannabinoid-based therapies in a range of CBD and/or THC ratios, doses and forms of delivery. RANGE OF INNOVATIVE DELIVERY SYSTEMS CREAM DEEP PENETRATION CAPSULES CREAM | LOCAL SUBLINGUAL 50mL | 1.7 fl. oz. SPRAY Natural 10 CAPSULES Rapid or 50
Slide 14: Pharmaceuticals
Pharmaceuticals Pipeline of indication specific products Pharmaceutical product pipeline following the traditional drug discovery and development process for eventual submission to the applicable government agencies, such as Health Canada or the FDA. Current Pipeline in Focus on 6 therapeutic areas
Slide 15: Avicanna Quality Standard (AQS)
Avicanna Quality Standard (AQS) Science first Our world-class research and development team’s approach to product development includes several stages of in vitro and in vivo testing to ensure all our products undergo many levels of optimization. Made for people Nothing but nature Our pharmaceutical p
Slide 16: Executive Management Team
Executive Management Team Aras Azadian, M.Mgmt Lucas Nosiglia, MFin Chief Executive Officer Chief Agricultural Officer Aras brings extensive senior management experience in the biotechnology Lucas has previous experience developing start-up companies in and financial sectors including his involvemen
Slide 17: Senior Scientific Team
Senior Scientific Team Dr. Justin Grant, PhD, MBA Dr. Amza Ali, MD, PhD, MBA SVP Clinical Development Dr. Ali is certified in Neurologist by the Federation of Royal Colleges of Dr. Grant has over 15 years experience in leading pharmaceutical research Physicians of the United Kingdom and launched the
Slide 18: Contact
CONTACT info@avicanna.com (647) 243 5283 Avicanna.com